Bide Pharmatech (SH:688073) Sou Hu Cai Jing·2025-10-16 20:43Group 1 - The core point of the news is that Shanghai Bid Pharmaceutical Co., Ltd. is taking measures to manage foreign exchange risks and optimize the use of idle funds from its initial public offering [1][2][3] Group 2 - On October 16, 2023, Bid Pharmaceutical's stock closed at 66.4 yuan, down 3.02%, with a turnover rate of 1.99% and a trading volume of 8,585 lots, amounting to 58.1291 million yuan [1] - The main capital flow on October 16 showed a net outflow of 184,400 yuan from institutional investors, accounting for 0.32% of the total trading volume, while retail investors had a net outflow of 1.066 million yuan, representing 1.83% of the total [1][3] - The company plans to conduct foreign exchange hedging activities with a maximum contract value of 600 million yuan, using its own funds, and has established a foreign exchange risk management system [1][3] - The company intends to use up to 200 million yuan of temporarily idle raised funds for cash management, investing in low-risk, liquid, and principal-protected financial products [2][3]